Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 72

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 72
---
 successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

We
may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties
that we identify as necessary for our current or future product candidates. We may face competition with regard to acquiring and in-licensing
third-party intellectual property rights, including from a number of more established companies. These established companies may have
a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property rights to us.
We also may be unable to acquire or in- license third-party intellectual property rights on terms that would allow us to make an appropriate
return on our investment.

We
may enter into collaboration agreements with U.S. and foreign academic institutions to accelerate development of our current or future
preclinical product candidates. Typically, these agreements include an option for the company to negotiate a license to the institution’s
intellectual property rights resulting from the collaboration. Even with such an option, we may be unable to negotiate a license within
the specified timeframe or under terms that are acceptable to us. If we are unable to license rights from a collaborating institution,
the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our desired program.

48

If
we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property
rights, we may need to abandon development of the related program and our business, financial condition and results of operations could
be materially and adversely affected.

Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection for licensed patents, pending patent applications and potential future
patent applications and patents could be reduced or eliminated for non-compliance with these requirements.

Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to
be paid to the United States Patent and Trademark Office “USPTO” and various governmental patent agencies outside of the
U.S. in several stages over the lifetime of the applicable patent and/or patent application. The USPTO and various non-U.S. governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent